<p>Immutep Ltd. has announced that it has reached 50% enrolment in its global TACTI-004 (KEYNOTE-F91) Phase III clinical trial. The study is evaluating eftilagimod alfa (efti) in combination with MSD’s KEYTRUDA® (pembrolizumab) and chemotherapy as a first-line therapy for advanced or metastatic non-small cell lung cancer (1L NSCLC). As of now, 378 patients have been enrolled across more than 140 clinical sites in 27 countries. The company stated that the futility analysis is scheduled for the first quarter of 2026, with full patient enrolment expected to be completed in the third quarter of 2026. No study results have been presented yet. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-043193), on February 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

SBIO

IMMP

Reuters

SPDR S&P Biotech

ALPS Medical Breakthrough

Immutep

VanEck Biotech ETF

iShares Biotechnology ETF

VG Health

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

Invesco Nasdaq Biotechnology ETF

Ark Genomic Revolution ETF

iShares Global Healthcare

Immutep Ltd

BlackRock, Inc.

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

Immutep Reaches 50% Enrolment in Global Phase III TACTI-004 Lung Cancer Trial